Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Age‐dependent and gender‐dependent antibody responses against SARS‐CoV ‐2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine

(2021) Evangelos Terpos et al.   AMERICAN JOURNAL OF HEMATOLOGY

Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors

(2021) Barliz Waissengrin et al.   LANCET ONCOLOGY

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

(2021) Leticia Monin et al.   LANCET ONCOLOGY

The Impact of COVID-19 on Patients With Cancer

(2021) Gladys M. Rodriguez et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors

(2021) Evangelos Terpos et al.   Journal of Hematology & Oncology

SARS-CoV-2 Variants and Vaccines

(2021) Philip R. Krause et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies

(2020) José Yélamos et al.   Cancers

Repositioning PARP inhibitors for SARS‐CoV‐2 infection (COVID‐19); a new multi‐pronged therapy for ARDS?

(2020) Nicola Curtin et al.   BRITISH JOURNAL OF PHARMACOLOGY

COVID-19 pathophysiology: A review

(2020) Koichi Yuki et al.   CLINICAL IMMUNOLOGY

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction

(2020) Chee Wah Tan et al.   NATURE BIOTECHNOLOGY

PARP-inhibitors in a non‐oncological indication as COVID-19: Are we aware about its potential role as anti-thrombotic drugs? The discussion is open

(2020) Ettore Capoluongo   BIOMEDICINE & PHARMACOTHERAPY

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

(2020) Merryn Voysey et al.   LANCET

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

A decade of clinical development of PARP inhibitors in perspective

(2019) J Mateo et al.   ANNALS OF ONCOLOGY